The novel dengue IgG/IgM rapid test that was developed in this study showed considerably higher sensitivities than those of the commercial test, i.e., 93.3% (14/15) and 100% (10/10) against anti-dengue IgG-positive and anti-dengue IgM-positive samples, respectively. This evidence concerns the gene CD40LG and dengue disease.